Eurobio Scientific S.A.
ALERS.PA · PAR
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Market Cap | €0 | €0 | €0 | €0 |
| - Cash | €0 | €0 | €0 | €0 |
| + Debt | €0 | €0 | €0 | €0 |
| Enterprise Value | €0 | €0 | €0 | €0 |
| Revenue | €0 | €0 | €0 | €0 |
| % Growth | -0.5% | 11.1% | 3.1% | – |
| Gross Profit | €0 | €0 | €0 | €0 |
| % Margin | 47% | 44.7% | 45.4% | 43% |
| EBITDA | €0 | €0 | €0 | €0 |
| % Margin | 13% | 10% | 15.6% | 19.4% |
| Net Income | €0 | €0 | €0 | €0 |
| % Margin | 3% | 0% | 5.4% | 3.7% |
| EPS Diluted | 0.23 | 0 | 0.4 | 0.22 |
| % Growth | 229,900% | -100% | 81.8% | – |
| Operating Cash Flow | €0 | €0 | €0 | €0 |
| Capital Expenditures | €0 | -€0 | -€0 | -€0 |
| Free Cash Flow | €0 | €0 | €0 | €0 |